amino acid · for joint pain
N-Acetyl Cysteine
Raises the antioxidant inside cartilage cells, meant to slow how fast they wear.
Say that in clinical terms
NAC replenishes glutathione in chondrocytes, protecting cartilage from oxidative degradation. It inhibits NF-kB and MMP activity in joint tissues, reduces IL-1beta-induced cartilage catabolism, and may slow osteoarthritic cartilage breakdown.
How strong is the research?
A 70-person trial in rheumatoid arthritis found no reduction in disease activity or joint pain.
2 papers read, 1 supporting, 1 against.
Who was studied: Likely animals or cell cultures. The cited paper reads as preclinical rather than a human trial.
How much to take
daily
600–1200 mg
NAC supports cartilage health through glutathione-mediated antioxidant protection and anti-inflammatory effects.
Before you take it
- No IOM/NIH ODS Tolerable Upper Intake Level established for NAC as a dietary supplement (not an essential nutrient); adverse effects are dose-dependent and increase above 1,200 mg/day.
- Potentiates organic nitrate drugs (nitroglycerin, isosorbide dinitrate) — severe hypotension documented in cardiology settings; avoid co-administration.
- Additive anticoagulant effect with warfarin (INR monitoring required); additive antiplatelet effect with aspirin.
- Antibiotic separation required: administer NAC at least 2 hours before or 4–6 hours after tetracyclines and quinolones to prevent chelation-mediated reduction in antibiotic absorption.
- GI side effects (nausea, vomiting, diarrhea) are dose-dependent; most common at oral doses above 1,200 mg/day.
- FDA drug-exclusion position (2020): FDA classified NAC as excluded from the dietary supplement definition because it was authorized as a new drug in 1963 (Mucomyst/acetylcysteine). As of 2022, FDA exercised enforcement discretion allowing existing NAC supplements on market; no final rule published as of 2025, leaving US supplement regulatory status unsettled.
- Rare anaphylactoid reactions with IV formulations; bronchospasm with inhaled/nebulized forms; both are uncommon via oral supplementation route.
- Joint pain patients commonly co-use NSAIDs (ibuprofen, naproxen); NAC's additive antiplatelet/anticoagulant effect with aspirin and non-aspirin NSAIDs may increase gastrointestinal bleeding risk in this population.
What we make of it
The journal publishes both animal and human work, and this reads as preclinical.
The detail
The paper appears in a journal covering both laboratory and clinical research, and the title reads as preclinical. It should not be treated as a human trial without confirming that.